Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna

A synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:

• at least one modified sugar moiety;
• at least one modified internucleotide linkage;
• at least one modified nucleotide, and combinations thereof;
• wherein said oligonucleotide is an antisense compound which specifically hybridizes to a natural antisense polynucleotide of a Sodium channel, voltage-gated, alpha subunit (SCN1A) gene selected from the group consisting of SEQ ID NO:
• 12 or of SEQ ID NO:
• 13, or of SEQ ID NO:
• 14, or of SEQ ID NO:15, or of SEQ ID NO:
• 16, or of SEQ ID NO:
• 17, or of SEQ ID NO:
• 18, or of SEQ ID NO:
• 19, or of SEQ ID NO:
• 20, or of SEQ ID NO:
• 21, or of SEQ ID NO:
• 22, or of SEQ ID NO:
• 23, or of SEQ ID NO:
• 24, or of SEQ ID NO:
• 25, or of SEQ ID NO:
• 26, or of SEQ ID NO:
• 27 or of SEQ ID NO:
• 28 and upregulates the function and or expression of the Sodium channel, voltage-gated, alpha subunit (SCN1A) gene in vivo or in vitro as compared to a normal control.

A method of treating a disease associated with at least one Sodium channel, voltage-gated, alpha subunit (SCN1A) polynucleotide and/or at least one encoded product thereof, comprising:

• administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide of 13 to 28 nucleotides in length that binds to, is 100% complementary to and specifically hybridizes to a natural antisense polynucleotide of said at least one Sodium channel, voltage-gated, alpha subunit (SCN1A) polynucleotide selected from the group consisting of SEQ ID NO:
• 12 or of SEQ ID NO:
• 13, or of SEQ ID NO:
• 14, or of SEQ ID NO:15, or of SEQ ID NO:
• 16, or of SEQ ID NO:
• 17, or of SEQ ID NO:
• 18, or of SEQ ID NO:
• 19, or of SEQ ID NO:
• 20, or of SEQ ID NO:
• 21, or of SEQ ID NO:
• 22, or of SEQ ID NO:
• 23, or of SEQ ID NO:
• 24, or of SEQ ID NO:
• 25, or of SEQ ID NO:
• 26, or of SEQ ID NO:
• 27 or of SEQ ID NO:
• 28;
• thereby upregulating a function of and/or the expression of the Sodium channel, voltage-gated, type I, alpha subunit (SCN1A) polynucleotide and wherein the at least one oligonucleotide comprises at least one oligonucleotide sequence set forth as SEQ ID NOS:
• 31, 33, 37, 40 to 92 thereby treating the disease associated with the at least one Sodium channel, voltage-gated, alpha subunit (SCNA) polynucleotide and/or at least one encoded product thereof.